Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Polycystic Ovary Syndrome 1Pancreatic Neoplasms 1Overweight 1Obesity 1Neoplasms 1Gastrointestinal Neoplasms 1Endometrial Neoplasms 1Endometrial Hyperplasia 1Colorectal Neoplasms 1Carcinoma, Hepatocellular 1

Interventions

Bevacizumab 35durvalumab 23atezolizumab 22Nivolumab 20lenvatinib 19tremelimumab 16Specimen Handling 14Magnetic Resonance Spectroscopy 12sintilimab 11pembrolizumab 9Ipilimumab 9tislelizumab 7Sorafenib 7cabozantinib 5X-Rays 5Immunoglobulin G 5Disulfides 5Cyclophosphamide 5regorafenib 4Radiotherapy 4Radiosurgery 4Radiation 4Oxaliplatin 4Immunotherapy 4Ethiodized Oil 4fludarabine 3donafenib 3Surgical Procedures, Operative 3Folfox protocol 3Fluorouracil 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Hepatocellular × semaglutide × 90 days × Clear all
NCT07627191 2026-06-05

GLP-1 RA Plus SOC Treatment in First-line, Metastatic Pancreatic, Colorectal, or Hepatocellular Cancer

University of Arizona

Phase EARLY_PHASE1 Not yet recruiting
30 enrolled
Gastrointestinal

Gastrointestinal Neoplasms, Carcinoma, Hepatocellular, Pancreatic Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡